Archive for March, 2023

Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease

Posted by amanda punzalan under Press (No Respond)

Data Further Supports Proof of Mechanism for MZE001, an Oral Substrate Reduction Therapy, with approximately 60% Reduction in Muscle Glycogen in Healthy Volunteers Non-invasive Biomarker Developed by Maze to Measure Glycogen Levels Suggests Approximately 1:1 Correlation Between PBMC Blood Test…